Redefining Treatment Goals and Patient Expectations in PsO

In this episode, ‘Redefining Treatment Goals and Patient Expectations in PsO,’ the expert dermatology panel explores how treatment expectations in plaque psoriasis have changed alongside advances in therapy. Faculty reflect on the progression of clinical trial benchmarks from PASI 50 to PASI 75, PASI 90, and increasingly PASI 100 as newer therapies have made deeper levels of skin clearance achievable.

The panel emphasizes that complete clearance is more than a clinical trial endpoint. Even limited residual psoriasis may remain visible, symptomatic, or disruptive to daily life, and patients may continue to experience meaningful quality-of-life impairment despite low overall disease burden. The experts discuss why complete clearance has therefore become an increasingly relevant treatment goal and how these higher expectations have influenced both clinical practice and patient conversations.

Beyond skin clearance, the discussion highlights symptoms such as itch, burning, and pain, as well as safety, tolerability, comorbidities, cost, and access. The faculty note that treatment success must account for the broader experience of living with psoriasis rather than relying solely on body surface area or a physician-assessed skin score. As newer therapies continue to improve disease control, the panel considers how goals that once seemed aspirational are becoming increasingly realistic.

The next episode in this series, ‘Overcoming Delays in Systemic Treatment Escalation for PsO,’ features the panelists examining why patients may remain on topical therapy despite persistent disease and why timely escalation to systemic treatment can matter.